Drug Patents Expiring in 2037
1. Drug name - AIRDUO DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10569034
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(14 years from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Treatment: NA
Dosage: POWDER;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.055MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.113MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.232MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
2. Drug name - AKYNZEO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10624911 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(14 years from now) | |
Treatment: NA
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
| EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
3. Drug name - AMZEEQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398641 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(14 years from now) | |
| US10849847 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(14 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 4% BASE | AEROSOL, FOAM;TOPICAL | Prescription |
4. Drug name - ARMONAIR DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10569034
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.055MG/INH | POWDER;INHALATION | Discontinued |
| 0.113MG/INH | POWDER;INHALATION | Discontinued |
| 0.232MG/INH | POWDER;INHALATION | Discontinued |
| 0.03MG/INH | POWDER;INHALATION | Discontinued |
5. Drug name - AUVI-Q
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10688244 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(15 years from now) | |
| US10842938 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(15 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Treatment: Method of treating an allergic reaction using an auto-injector
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.1MG/DELIVERY | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | Prescription |
| EQ 0.15MG/DELIVERY | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | Prescription |
| EQ 0.3MG/DELIVERY | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | Prescription |
6. Drug name - AZSTARYS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10584112 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10759778 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(15 years from now) | |
| US10954213 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(15 years from now) | |
| US10858341 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(15 years from now) | |
| US10584113 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(15 years from now) | |
Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5.2MG BASE;EQ 26.1MG BASE | CAPSULE;ORAL | Prescription |
| EQ 7.8MG BASE;EQ 39.2MG BASE | CAPSULE;ORAL | Prescription |
| EQ 10.4MG BASE;EQ 52.3MG BASE | CAPSULE;ORAL | Prescription |
7. Drug name - BRUKINSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 80MG | CAPSULE;ORAL | Prescription |
8. Drug name - CABOMETYX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(14 years from now) | |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | TABLET;ORAL | Prescription |
| EQ 40MG BASE | TABLET;ORAL | Prescription |
| EQ 60MG BASE | TABLET;ORAL | Prescription |
9. Drug name - CALCIUM GLUCONATE IN SODIUM CHLORIDE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342813 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(14 years from now) | |
| US10130646 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 1GM/50ML (20MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 1GM/100ML (10MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 2GM/100ML (20MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
10. Drug name - CEQUA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10918694 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.09% | SOLUTION;OPHTHALMIC | Prescription |
11. Drug name - DEFINITY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(14 years from now) | |
| US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(14 years from now) | |
| US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(14 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 6.52MG/ML | INJECTABLE;INTRAVENOUS | Prescription |
12. Drug name - DRIZALMA SPRINKLE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10413525 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(14 years from now) | |
| US11202772 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(14 years from now) | |
| US9839626 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(14 years from now) | |
| US10959982 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(14 years from now) | |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | CAPSULE, DELAYED REL PELLETS;ORAL | Prescription |
| EQ 30MG BASE | CAPSULE, DELAYED REL PELLETS;ORAL | Prescription |
| EQ 40MG BASE | CAPSULE, DELAYED REL PELLETS;ORAL | Prescription |
| EQ 60MG BASE | CAPSULE, DELAYED REL PELLETS;ORAL | Prescription |
13. Drug name - ESBRIET
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 267MG | TABLET;ORAL | Prescription |
| 534MG | TABLET;ORAL | Discontinued |
| 801MG | TABLET;ORAL | Prescription |
14. Drug name - EVEKEO ODT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10441554 | ARBOR PHARMS LLC | Oral amphetamine composition |
Mar, 2037
(14 years from now) | |
| US11160772 | ARBOR PHARMS LLC | Oral amphetamine composition |
Mar, 2037
(14 years from now) | |
Drugs and Companies using AMPHETAMINE SULFATE ingredient
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG | TABLET, ORALLY DISINTEGRATING;ORAL | Discontinued |
| 5MG | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
| 10MG | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
| 15MG | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
| 20MG | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
15. Drug name - FINTEPLA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603290 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US11040018 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Treatment: Use in combination with cannabidiol for the treatment of seizures associated with dravet syndrome
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2.2MG BASE/ML | SOLUTION;ORAL | Prescription |
16. Drug name - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10293047 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(15 years from now) | |
| US10842872 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(15 years from now) | |
| US10632197 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(15 years from now) | |
Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient
Treatment: Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic; Procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic.
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.4%;0.3% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
17. Drug name - GALAFOLD
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076514 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(14 years from now) | |
| US11234972 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(14 years from now) | |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 123MG BASE | CAPSULE;ORAL | Prescription |
18. Drug name - GIAPREZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219662 | LA JOLLA PHARMA | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II |
Jan, 2037
(14 years from now) | |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
Treatment: Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) | SOLUTION;INTRAVENOUS | Discontinued |
19. Drug name - GLOPERBA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10226423 | ROMEG | Colchicine drug-to-drug interactions |
Dec, 2037
(15 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.6MG/5ML | SOLUTION;ORAL | Prescription |
20. Drug name - GOPRELTO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857095 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10413505 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10420760 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10149843 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10933060 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10987347 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10894012 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10231961 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US11040032 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; method of administering a local anesthetic to the mucous membranes in patients with renal impairment; method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method of administering a local anesthetic to the mucous membranes; method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment
Dosage: SOLUTION;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| 4% | SOLUTION;NASAL | Prescription |
21. Drug name - HEMADY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537585 | DEXCEL PHARMA | Compositions comprising dexamethasone |
Dec, 2037
(15 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET;ORAL | Prescription |
22. Drug name - INGREZZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(15 years from now) | |
| US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(15 years from now) | |
| US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(15 years from now) | |
| US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(15 years from now) | |
| US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(15 years from now) | |
| US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(15 years from now) | |
| US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(15 years from now) | |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
Treatment: Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; treatment of tardive dyskinesia; Treatment of tardive dyskinesia; method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer; Treatment of tardive dyskinesia
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | CAPSULE;ORAL | Prescription |
| EQ 60MG BASE | CAPSULE;ORAL | Prescription |
| EQ 80MG BASE | CAPSULE;ORAL | Prescription |
23. Drug name - KATERZIA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959991 | AZURITY | Amlodipine formulations |
Oct, 2037
(15 years from now) | |
| US10952998 | AZURITY | Amlodipine formulations |
Oct, 2037
(15 years from now) | |
| US10894039 | AZURITY | Amlodipine formulations |
Oct, 2037
(15 years from now) | |
| US10695329 | AZURITY | Amlodipine formulations |
Oct, 2037
(15 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Treatment: Angina pectoris; angina; Treatment of hypertension; method of treating hypertension
Dosage: SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1MG BASE/ML | SUSPENSION;ORAL | Prescription |
24. Drug name - KORLYM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10151763 | CORCEPT THERAP | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome |
Jan, 2037
(14 years from now) | |
| US10195214 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(14 years from now) | |
| US10842800 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(14 years from now) | |
Drugs and Companies using MIFEPRISTONE ingredient
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 300MG | TABLET;ORAL | Prescription |
25. Drug name - LEXETTE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10857159
(Pediatric) | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
May, 2037
(14 years from now) | |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Treatment: NA
Dosage: AEROSOL, FOAM;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.05% | AEROSOL, FOAM;TOPICAL | Prescription |
26. Drug name - LONSURF
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10960004 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(14 years from now) | |
| US10456399 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(14 years from now) | |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
Treatment: Method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 6.14MG BASE;15MG | TABLET;ORAL | Prescription |
| EQ 8.19MG BASE;20MG | TABLET;ORAL | Prescription |
27. Drug name - LUPKYNIS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(15 years from now) | |
Drugs and Companies using VOCLOSPORIN ingredient
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 7.9MG | CAPSULE;ORAL | Prescription |
28. Drug name - MYFEMBREE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033551 | MYOVANT SCIENCES | Methods of treating uterine fibroids |
Sep, 2037
(15 years from now) | |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG;0.5MG;40MG | TABLET;ORAL | Prescription |
29. Drug name - NUPLAZID
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(14 years from now) | |
| US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(14 years from now) | |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 10MG BASE | TABLET;ORAL | Prescription |
| EQ 17MG BASE | TABLET;ORAL | Discontinued |
30. Drug name - NUZYRA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(14 years from now) | |
| US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(15 years from now) | |
| US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(15 years from now) | |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
Treatment: Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 150MG BASE | TABLET;ORAL | Prescription |
31. Drug name - ORGOVYX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786501 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(15 years from now) | |
| US10449191 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(15 years from now) | |
Drugs and Companies using RELUGOLIX ingredient
Treatment: Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 120MG | TABLET;ORAL | Prescription |
32. Drug name - OTIPRIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040004 | ALK ABELLO | Otic gel formulations for treating otitis externa |
Nov, 2037
(15 years from now) | |
Drugs and Companies using CIPROFLOXACIN ingredient
Treatment: The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus
Dosage: INJECTABLE, SUSPENSION;OTIC
| Strength | Dosage | Availability |
|---|---|---|
| 6% (60MG/ML) | INJECTABLE, SUSPENSION;OTIC | Prescription |
33. Drug name - OXBRYTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10493035 | GLOBAL BLOOD THERAPS | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Oct, 2037
(15 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 500MG | TABLET;ORAL | Prescription |
34. Drug name - PIZENSY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10806743 | BRAINTREE LABS | Method of administering lactitol to reduce plasma concentration of lactitol |
May, 2037
(14 years from now) | |
Drugs and Companies using LACTITOL ingredient
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: FOR SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10GM | FOR SOLUTION;ORAL | Discontinued |
35. Drug name - PYLARIFY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 50ML (1-80mCi/ML) | SOLUTION;INTRAVENOUS | Prescription |
36. Drug name - RETEVMO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10112942 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(15 years from now) | |
| CN110382494A | LOXO ONCOLOGY INC | Substituted Pyrazole And [1-A] Pyridine Compound As The Ret Kinase Inhibitor |
Oct, 2037
(15 years from now) | |
| CN110382494B | LOXO ONCOLOGY INC | Substituted Pyrazolo [1, 5-A] Pyridine Compound As Ret Kinase Inhibitor |
Oct, 2037
(15 years from now) | |
| EP3523301A1 | LOXO ONCOLOGY INC | Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors |
Oct, 2037
(15 years from now) | |
| EP3523301B1 | LOXO ONCOLOGY INC | Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors |
Oct, 2037
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10172851 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(15 years from now) | |
| US10137124 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(15 years from now) | |
Drugs and Companies using SELPERCATINIB ingredient
Treatment: Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate)
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 40MG | CAPSULE;ORAL | Prescription |
| 80MG | CAPSULE;ORAL | Prescription |
37. Drug name - REYVOW
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(15 years from now) | |
| EP3551617B1 | ELI LILLY AND CO | Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists |
Dec, 2037
(15 years from now) | |
| EP3551617A1 | ELI LILLY AND CO | Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists |
Dec, 2037
(15 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 50MG BASE | TABLET;ORAL | Prescription |
| EQ 100MG BASE | TABLET;ORAL | Prescription |
| EQ 200MG BASE | TABLET;ORAL | Discontinued |
38. Drug name - ROZLYTREK
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
| CN109153669A | GENENTECH INC | N - [5 - (3, 5-Difluoro-Benzyl) -1H - Indazol - -3 - Yl]--4-(4-Methyl-Piperazin - -1 - Yl)--2-(Tetrahydropyran - -4 - Ylamino) - Form |
May, 2037
(14 years from now) | |
| CN109153669B | GENENTECH INC | New Crystal Form Of Benzamide Compound |
May, 2037
(14 years from now) | |
| EP3464276A1 | GENENTECH INC | New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide |
May, 2037
(14 years from now) | |
| EP3464276B1 | GENENTECH INC | New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide |
May, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
Drugs and Companies using ENTRECTINIB ingredient
Treatment: Treatment of ros1-positive non-small cell lung cancer; treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | CAPSULE;ORAL | Prescription |
| 200MG | CAPSULE;ORAL | Prescription |
39. Drug name - SAXENDA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(14 years from now) | |
|
US9968659
(Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
40. Drug name - SUNOSI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10195151 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
| US10512609 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 75MG BASE | TABLET;ORAL | Prescription |
| EQ 150MG BASE | TABLET;ORAL | Prescription |
41. Drug name - SUTAB
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10143656 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(14 years from now) | |
| US11033498 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(14 years from now) | |
Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient
Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.225GM;0.188GM;1.479GM | TABLET;ORAL | Prescription |
42. Drug name - TIROSINT-SOL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537538 | INSTITUT BIOCHIMIQUE | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(14 years from now) | |
| US11096913 | INSTITUT BIOCHIMIQUE | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 13MCG/ML | SOLUTION;ORAL | Prescription |
| 25MCG/ML | SOLUTION;ORAL | Prescription |
| 37.5MCG/ML | SOLUTION;ORAL | Prescription |
| 44MCG/ML | SOLUTION;ORAL | Prescription |
| 50MCG/ML | SOLUTION;ORAL | Prescription |
| 62.5MCG/ML | SOLUTION;ORAL | Prescription |
| 75MCG/ML | SOLUTION;ORAL | Prescription |
| 88MCG/ML | SOLUTION;ORAL | Prescription |
| 100MCG/ML | SOLUTION;ORAL | Prescription |
| 112MCG/ML | SOLUTION;ORAL | Prescription |
| 125MCG/ML | SOLUTION;ORAL | Prescription |
| 137MCG/ML | SOLUTION;ORAL | Prescription |
| 150MCG/ML | SOLUTION;ORAL | Prescription |
| 175MCG/ML | SOLUTION;ORAL | Prescription |
| 200MCG/ML | SOLUTION;ORAL | Prescription |
43. Drug name - TRIKAFTA (COPACKAGED)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10793547 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(15 years from now) | |
| EP3551622B1 | VERTEX PHARMS INC | Modulator Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process For Making The Modulator |
Dec, 2037
(15 years from now) | |
| EP3551622A1 | VERTEX PHARMS INC | Modulator Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process For Making The Modulator |
Dec, 2037
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11179367 | VERTEX PHARMS INC | Pharmaceutical compositions for treating cystic fibrosis |
Dec, 2037
(15 years from now) | |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a composition according to at least one of claims 1-9 of us11179367
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG,37.5MG,25MG; 75MG | TABLET;ORAL | Prescription |
| 100MG,75MG,50MG; 150MG | TABLET;ORAL | Prescription |
44. Drug name - VICTOZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(14 years from now) | |
|
US9968659
(Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
45. Drug name - VITRAKVI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10668072 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(14 years from now) | |
| US10045991 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(14 years from now) | |
| US10137127 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(14 years from now) | |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
Treatment: Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE/ML | SOLUTION;ORAL | Prescription |
46. Drug name - VOSEVI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912814 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(14 years from now) | |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 400MG;100MG;100MG | TABLET;ORAL | Prescription |
47. Drug name - XERAVA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10961190 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(15 years from now) | |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
Treatment: NA
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 50MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
| EQ 100MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
48. Drug name - XOFLUZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
| 80MG | TABLET;ORAL | Prescription |
49. Drug name - ZULRESSO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940156 | SAGE THERAP | Neuroactive steroids, compositions, and uses thereof |
Mar, 2037
(14 years from now) | |
Drugs and Companies using BREXANOLONE ingredient
Treatment: Method of treating postpartum depression
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/20ML (5MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.